Pharmaceutical sector : The CFI wants the Commission to take into account the specificity of the pharmaceutical sector to appreciate the concrete effects of the restrictions to parallel trade (GSK)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. He cites the conclusions reached by the Court of First Instance in a case concerning the control by producers of pharmaceutical products of parallel trade in medicines between Spain, where the administration sets maximum prices, and other Member States, in particular the United Kingdom, where prices are set at a higher level with a view to allocating the surplus